EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of PI3K-p110α Inhibitor Alpelisib in the Differentiation and Effector Functions of M-CSF and GM-CSF Macrophages

Cristina Villa-Gómez iD, Verónica Bermejo, Inmaculada Márquez-Leiva, Jana Baranda iD, Alejandro C Briones iD, Isabel Cervera, Jordi Ochando, José María Rojo iD, Pilar Portolés iD

International Journal of Molecular Sciences · 07.05.2026 · 27 (10) · 4171

DOI: 10.3390/ijms27104171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.05.2026. Verfasst von Cristina Villa-Gómez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, National Centre for Microbiology (CNM), Carlos III Health Institute (ISCIII), 28220 Madrid, Spain. Hauptthemen laut MEDLINE: Granulocyte-Macrophage Colony-Stimulating Factor, Macrophages, Cell Differentiation, Macrophage Colony-Stimulating Factor. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Accion Estratégica en Salud Intramural (AESI) del Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphatidylinositol-3-kinases (PI3Ks) are heterodimers of catalytic and regulatory subunits that regulate cell metabolism, activation, and survival. PI3K, particularly the p110α catalytic isoform, is frequently mutated in cancer, and highly specific inhibitors such as alpelisib are currently used in oncology and in PIK3CA-related overgrowth disorders. Given the relevance of macrophages in anti-tumor immunity, we examined the impact of alpelisib on murine monocytes’ intracellular signaling and on in vitro differentiation, polarization, and effector functions of macrophages. Real-time qPCR (RT-qPCR) showed comparable relative expression of PI3K isoforms (p110α, p110β, p110δ, p110γ and p85) in bone marrow monocytes and in macrophages differentiated with macrophage colony-stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). However, alpelisib increased p110α, p110β, and p85 relative gene expression (2–3-fold) during M-CSF-dependent differentiation. Functionally, alpelisib-treated M-CSF macrophages displayed enhanced interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) secretion and reduced IL-10 production after lipopolysaccharide (LPS) plus interferon gamma (IFN-γ) or LPS stimulation. In contrast, GM-CSF macrophages differentiated with alpelisib secreted lower levels of IL-6 and TNF-α and reduced inducible nitric oxide synthase (iNOS) and arginase-1 (Arg-1) gene expression. Additionally, cytokine profiles (IL-2, IL-6, IFN-γ and IL-10) were altered when alpelisib-treated macrophages were cocultured with CD4+ T cells under either antigen-specific or polyclonal activation conditions, indicating that the inhibitor modifies both differentiation and subsequent effector interactions of the macrophages. Thus, alpelisib induces lasting effects on macrophage differentiation and function, with potential implications in tumor-associated macrophages that develop under M-CSF or GM-CSF-rich cancer microenvironments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulocyte-Macrophage Colony-Stimulating FactorMacrophagesCell DifferentiationMacrophage Colony-Stimulating FactorClass I Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsAnimalsMiceMonocytesNitric Oxide Synthase Type IICytokinesSignal TransductionPhosphatidylinositol 3-KinasesThiazoles

Stichwörter der Autor:innen

GM-CSFM-CSFPI3K-p110αT lymphocytealpelisib (BYL719)class I PI3-kinasesmacrophagemonocytephosphatidylinositol-3-kinases

Substanzen

Granulocyte-Macrophage Colony-Stimulating FactorMacrophage Colony-Stimulating FactorClass I Phosphatidylinositol 3-KinasesAlpelisibPhosphoinositide-3 Kinase InhibitorsNitric Oxide Synthase Type IICytokinesPhosphatidylinositol 3-KinasesThiazoles

Autor:innen und Institutionen

  • Immunology Department, National Centre for Microbiology (CNM), Carlos III Health Institute (ISCIII), 28220 Madrid, Spain.
  • Microbiology Section, Department of Pharmaceutical and Health Sciences, Faculty of Pharmacy, San Pablo-CEU University, 28668 Madrid, Spain.
  • Department of Immunology, Complutense University School of Medicine, i+12 Research Institute, 28040 Madrid, Spain.
  • Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Margarita Salas Center for Biological Research (CIB), Spanish National Research Council (CSIC), 28040 Madrid, Spain.

ORCID-Profile: Cristina Villa-Gómez, Jana Baranda, Alejandro C Briones, José María Rojo, Pilar Portolés

Förderung

  • Accion Estratégica en Salud Intramural (AESI) del Instituto de Salud Carlos III

Zitieren

APA

Villa-Gómez, C., Bermejo, V., Márquez-Leiva, I., Baranda, J., Briones, A. C., Cervera, I., Ochando, J., Rojo, J. M., & Portolés, P. (2026). Effect of PI3K-p110α Inhibitor Alpelisib in the Differentiation and Effector Functions of M-CSF and GM-CSF Macrophages. International Journal of Molecular Sciences, 27(10), 4171. https://doi.org/10.3390/ijms27104171

Vancouver

Villa-Gómez C, Bermejo V, Márquez-Leiva I, Baranda J, Briones AC, Cervera I, et al. Effect of PI3K-p110α Inhibitor Alpelisib in the Differentiation and Effector Functions of M-CSF and GM-CSF Macrophages. International Journal of Molecular Sciences. 2026;27(10):4171. doi:10.3390/ijms27104171

BibTeX
@article{VillaGmez2026,
  author = {Villa-Gómez, Cristina and Bermejo, Verónica and Márquez-Leiva, Inmaculada and Baranda, Jana and Briones, Alejandro C and Cervera, Isabel and Ochando, Jordi and Rojo, José María and Portolés, Pilar},
  title = {Effect of PI3K-p110α Inhibitor Alpelisib in the Differentiation and Effector Functions of M-CSF and GM-CSF Macrophages},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4171},
  doi = {10.3390/ijms27104171}
}
Kostenlos starten →